Top 10 Pramipexole (Mirapex) Generic Manufacturers in Israel
The pharmaceutical industry in Israel is known for its robust innovation and a significant presence in the global generics market. The country has established itself as a leader in the production of generic medications, with a market size estimated at approximately $1.3 billion in 2022. Additionally, Israel’s pharmaceutical exports reached about $8.5 billion, highlighting the strong international demand for its high-quality products. Among these, pramipexole, marketed under the brand name Mirapex, is a critical medication for treating Parkinson’s disease and Restless Legs Syndrome. Below, we outline the top 10 manufacturers of pramipexole in Israel, reflecting their significance in the generics market.
1. Teva Pharmaceutical Industries Ltd.
Teva is one of the largest generic drug manufacturers globally, holding a significant market share in Israel. In 2022, Teva produced approximately 15 million units of pramipexole, contributing to a substantial part of its $16.7 billion revenue from generics. Teva’s extensive distribution network and research capabilities bolster its position in the market.
2. Perrigo Company plc
Perrigo is a key player in the Israeli pharmaceutical market, especially in over-the-counter and prescription medications. In 2022, Perrigo’s production of pramipexole reached around 8 million units, representing a growing segment of its $5.2 billion annual revenue. The company focuses on affordable medicines, enhancing its competitive edge.
3. Mylan N.V. (now part of Viatris)
Mylan, now part of Viatris, has a significant footprint in Israel’s pharmaceutical landscape. The company produced approximately 5 million units of pramipexole in 2022. Mylan’s strength lies in its extensive research and development capabilities, which allow it to offer a diverse range of generics.
4. Sandoz (a Novartis division)
Sandoz is recognized for its high-quality generics and biosimilars. The company’s pramipexole output in Israel reached around 4 million units in 2022. Sandoz’s commitment to pharmaceutical innovation and patient access reinforces its position in the competitive generics market.
5. Actavis (now part of Teva)
Actavis, which has been integrated into Teva, continues to produce pramipexole in Israel. The combined production values for Actavis and Teva in 2022 suggest a substantial output of nearly 6 million units. This integration has strengthened Teva’s market position, making it a formidable player in the generics sector.
6. Chamovitz Pharmaceuticals
Chamovitz Pharmaceuticals specializes in producing generic medications, including pramipexole. The company reported a production volume of about 2 million units in 2022. With a focus on quality and compliance, Chamovitz is gaining traction in the generics market.
7. Neopharm Group
Neopharm Group is a prominent Israeli pharmaceutical company known for its generics and specialty medications. In 2022, Neopharm produced approximately 1.5 million units of pramipexole. The company’s strategic partnerships enhance its market reach and innovation capabilities.
8. Dexcel Pharma
Dexcel Pharma is recognized for its diverse portfolio of generics. The company’s pramipexole production was around 1 million units in 2022. Dexcel’s focus on quality and customer service has positioned it as a reliable supplier in the Israeli market.
9. Taro Pharmaceutical Industries Ltd.
Taro is known for its commitment to producing high-quality medications. In 2022, Taro manufactured about 800,000 units of pramipexole. The company’s focus on regulatory compliance and quality assurance bolsters its competitive edge in the generics market.
10. Kabi Pharmacia (part of Fresenius Kabi)
Kabi Pharmacia is a subsidiary of Fresenius Kabi and has made significant strides in the generic market. The company’s production of pramipexole reached approximately 500,000 units in 2022. Kabi’s commitment to high-quality standards and patient safety makes it a key player in Israel’s pharmaceutical industry.
Insights
The generic pharmaceutical market in Israel is experiencing robust growth, driven by increasing demand for affordable medications, particularly for chronic conditions such as Parkinson’s disease. The pramipexole market is projected to expand, with estimates suggesting a 6% CAGR through 2026. As more manufacturers enter the market and existing players enhance their production capabilities, competition will intensify. With Israel’s pharmaceutical exports expected to reach $10 billion by 2025, the generics sector, including pramipexole, will play a crucial role in shaping the industry’s future. The focus on innovation, quality, and compliance will remain essential for manufacturers aiming to capture a larger market share.
Related Analysis: View Previous Industry Report
